Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

Research output: Contribution to journalArticle

Standard

Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. / Kolberg, Matthias; Høland, Maren; Agesen, Trude H; Brekke, Helge R; Liestøl, Knut; S Hall, Kirsten; Mertens, Fredrik; Picci, Piero; Smeland, Sigbjørn; Lothe, Ragnhild A.

In: Neuro-Oncology, Vol. 15, No. 2, 2013, p. 135-147.

Research output: Contribution to journalArticle

Harvard

Kolberg, M, Høland, M, Agesen, TH, Brekke, HR, Liestøl, K, S Hall, K, Mertens, F, Picci, P, Smeland, S & Lothe, RA 2013, 'Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.', Neuro-Oncology, vol. 15, no. 2, pp. 135-147. https://doi.org/10.1093/neuonc/nos287

APA

Kolberg, M., Høland, M., Agesen, T. H., Brekke, H. R., Liestøl, K., S Hall, K., ... Lothe, R. A. (2013). Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. Neuro-Oncology, 15(2), 135-147. https://doi.org/10.1093/neuonc/nos287

CBE

MLA

Vancouver

Author

Kolberg, Matthias ; Høland, Maren ; Agesen, Trude H ; Brekke, Helge R ; Liestøl, Knut ; S Hall, Kirsten ; Mertens, Fredrik ; Picci, Piero ; Smeland, Sigbjørn ; Lothe, Ragnhild A. / Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1. In: Neuro-Oncology. 2013 ; Vol. 15, No. 2. pp. 135-147.

RIS

TY - JOUR

T1 - Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.

AU - Kolberg, Matthias

AU - Høland, Maren

AU - Agesen, Trude H

AU - Brekke, Helge R

AU - Liestøl, Knut

AU - S Hall, Kirsten

AU - Mertens, Fredrik

AU - Picci, Piero

AU - Smeland, Sigbjørn

AU - Lothe, Ragnhild A

PY - 2013

Y1 - 2013

N2 - There are conflicting reports as to whether malignant peripheral nerve sheath tumor (MPNST) patients with neurofibromatosis type 1 (NF1) have worse prognosis than non-NF1 MPNST patients. Large clinical studies to address this problem are lacking due to the rareness of MPNST. We have performed meta-analyses testing the effect of NF1 status on MPNST survival based on publications from the last 50 years, including only nonoverlapping patients reported from each institution. In addition, we analyzed survival characteristics for 179 MPNST patients from 3 European sarcoma centers. The meta-analyses including data from a total of 48 studies and >1800 patients revealed a significantly higher odds ratio for overall survival (OR(OS)) and disease-specific survival (OR(DSS)) in the non-NF1 group (OR(OS) = 1.75, 95% confidence interval [CI] = 1.28-2.39, and OR(DSS) = 1.68, 95% CI = 1.18-2.40). However, in studies published in the last decade, survival in the 2 patient groups has been converging, as especially the NF1 group has shown improved prognosis. For our own MPNST patients, NF1 status had no effect on overall or disease-specific survival. The compiled literature from 1963 to the present indicates a significantly worse outcome of MPNST in patients with NF1 syndrome compared with non-NF1 patients. However, survival for the NF1 patients has improved in the last decade, and the survival difference is diminishing. These observations support the hypothesis that MPNSTs arising in NF1 and non-NF1 patients are not different per se. Consequently, we suggest that the choice of treatment for MPNST should be independent of NF1 status.

AB - There are conflicting reports as to whether malignant peripheral nerve sheath tumor (MPNST) patients with neurofibromatosis type 1 (NF1) have worse prognosis than non-NF1 MPNST patients. Large clinical studies to address this problem are lacking due to the rareness of MPNST. We have performed meta-analyses testing the effect of NF1 status on MPNST survival based on publications from the last 50 years, including only nonoverlapping patients reported from each institution. In addition, we analyzed survival characteristics for 179 MPNST patients from 3 European sarcoma centers. The meta-analyses including data from a total of 48 studies and >1800 patients revealed a significantly higher odds ratio for overall survival (OR(OS)) and disease-specific survival (OR(DSS)) in the non-NF1 group (OR(OS) = 1.75, 95% confidence interval [CI] = 1.28-2.39, and OR(DSS) = 1.68, 95% CI = 1.18-2.40). However, in studies published in the last decade, survival in the 2 patient groups has been converging, as especially the NF1 group has shown improved prognosis. For our own MPNST patients, NF1 status had no effect on overall or disease-specific survival. The compiled literature from 1963 to the present indicates a significantly worse outcome of MPNST in patients with NF1 syndrome compared with non-NF1 patients. However, survival for the NF1 patients has improved in the last decade, and the survival difference is diminishing. These observations support the hypothesis that MPNSTs arising in NF1 and non-NF1 patients are not different per se. Consequently, we suggest that the choice of treatment for MPNST should be independent of NF1 status.

KW - meta-analysis

KW - NF1

KW - MPNST

KW - neurofibromatosis

U2 - 10.1093/neuonc/nos287

DO - 10.1093/neuonc/nos287

M3 - Article

VL - 15

SP - 135

EP - 147

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1523-5866

IS - 2

ER -